In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The role of intravascular imaging methods during perfomance percutaneous coronary interventions in patients with pseudobifurcation stenosis of the left main coronary artery

Session Poster Session 3

Speaker Associate Professor Daniil Maximkin

Congress : Heart Failure 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Poster Session
  • FP Number : P1788

Authors : Z Shugushev (Moscow,RU), D A Maximkin (Moscow,RU), A Chepurnoy (Moscow,RU), O Safonova (Moscow,RU), A Faibushevich (Moscow,RU), V Baranovich (Moscow,RU), G Veretnik (Moscow,RU)

Authors:
Z Shugushev1 , D A Maximkin1 , A Chepurnoy1 , O Safonova1 , A Faibushevich1 , V Baranovich1 , G Veretnik1 , 1RUDN University - Moscow - Russian Federation ,

Citation:

Aim: to increase the effectiveness of endovascular treatment in patients with ostium coronary artery lesions.

Methods: 150 patients were included in the study. Inclusion criteria: ostium atheros?lerotic lesions of LAD or LCx > 75% according to OCT or IVUS; stable angina II-III functional class (CCS); silent myocardial ischemia. The main included 108 patients, who were randomized into 2 groups. In I group (n=54) according to IVUS, atherosclerotic plaque spread from the ostium of LAD and/or LCx to the LMCA, and in group II (n = 54) - the plaque did not spread into the LMCA. In Group I all patients were initially treated with «Provisional T» stenting of the LMCA, and in Group II - stenting of the ostium LAD or LCx. In retrospectively, the third (III) control group (n=42) was formed, where the stenting of the ostium of LAD or LCx was performed without IVUS.

Results: There were no complications associated with PCI in long-term period results (over a period 30.04±12.04 months). The survival was 100% in all groups. There was no conversion to complete bifurcation stenting. In comparative analysis of Group I and II there were non significant differences of MACE’s and restenosis (2.3 and 7.5% respectively; p>0,05). In group III (without IVUS and OCT) where 18 patients with precision stenting and 22 with Provisional T stenting. There were significant difference for frequency of restenosis in this group (9 and 27.7% respectively; p<0,05). In comparative analysis of Group I and III (n= 22 doing the Provisional T stenting) there were more frequency of restenosis in group III, but this data wasn’t significant difference (0 and 9% respectively p>0,05). However, in comparative analysis of Group II and III (doing the precision stenting) there were significant difference of frequency of restenosis and TLR (2.5 and 22.2% respectively; p<0,05). The data of Minimal lumen area (MLA) in long-term period has significant difference in patients with precision ostium stenting compared to MLA data after PCI (LCx 5.38 vs 4.76 mm2; p<0,05 and LAD 6.28 vs 5.88 mm2; p<0,05). And the results of measuring the LAD and LCx after doing the provisional T stenting in long term period and after PCI were not valuable (p<0,05). Conclusion: the use of intravascular imaging methods for the analysis of the ostium lesions of coronary artery allows us to choose the optimal stenting technique and also reliably improve the long-term results of endovascular intervention by reducing the incidence of stent restenosis and MACE.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are